Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Scholar Rock
SRRK
$6.46B
| $843K | ﹤0.01% |
46,300
+9,400
| +25% | +$160K |
|
|
TSC
2202
DELISTED
TriState Capital Holdings, Inc.
TSC
| $841K | ﹤0.01% |
53,538
+8,100
| +18% | +$110K |
|
2203
Passage Bio
PASG
$14.7M
| $839K | ﹤0.01% |
+1,535
| New | +$690K |
|
|
RST
2204
DELISTED
ROSETTA STONE INC
RST
| $833K | ﹤0.01% |
49,400
+8,000
| +19% | +$134K |
|
2205
Resources Connection
RGP
$145M
| $832K | ﹤0.01% |
69,500
+10,500
| +18% | +$114K |
|
2206
Revolution Medicines
RVMD
$43.3B
| $830K | ﹤0.01% |
+26,300
| New | +$827K |
|
2207
Comtech Telecommunications
CMTL
$52.7M
| $828K | ﹤0.01% |
49,000
+1,700
| +4% | +$28.7K |
|
2208
Waterstone Financial
WSBF
$385M
| $828K | ﹤0.01% |
55,800
+8,200
| +17% | +$116K |
|
2209
Agilysys
AGYS
$3.25B
| $823K | ﹤0.01% |
45,900
+6,900
| +18% | +$129K |
|
2210
Aprea Therapeutics
APRE
$8.31M
| $822K | ﹤0.01% |
+1,060
| New | +$696K |
|
2211
Q32 Bio
QTTB
$458M
| $822K | ﹤0.01% |
3,006
+900
| +43% | +$240K |
|
|
ALTA
2212
DELISTED
Altabancorp
ALTA
| $822K | ﹤0.01% |
36,600
+5,500
| +18% | +$114K |
|
|
FSB
2213
DELISTED
Franklin Financial Network, Inc.
FSB
| $821K | ﹤0.01% |
31,900
+4,800
| +18% | +$112K |
|
2214
Forrester Research
FORR
$224M
| $819K | ﹤0.01% |
25,550
+3,900
| +18% | +$124K |
|
2215
Customers Bancorp
CUBI
$2.82B
| $816K | ﹤0.01% |
67,900
+10,200
| +18% | +$114K |
|
2216
Clear Channel Outdoor Holdings
CCO
$1.18B
| $812K | ﹤0.01% |
780,300
+57,200
| +8% | +$53.8K |
|
2217
World Acceptance Corp
WRLD
$875M
| $812K | ﹤0.01% |
12,400
+900
| +8% | +$56.3K |
|
|
UBA
2218
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $811K | ﹤0.01% |
68,236
+10,300
| +18% | +$133K |
|
|
HIBB
2219
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $810K | ﹤0.01% |
38,700
+4,400
| +13% | +$73.3K |
|
|
GOGL
2220
DELISTED
Golden Ocean Group
GOGL
| $808K | ﹤0.01% |
210,922
+45,217
| +27% | +$159K |
|
|
BDSI
2221
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $805K | ﹤0.01% |
184,700
+27,800
| +18% | +$125K |
|
2222
McEwen Inc
MUX
$1.14B
| $803K | ﹤0.01% |
79,533
+18,080
| +29% | +$168K |
|
|
BSTC
2223
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $803K | ﹤0.01% |
13,100
+2,600
| +25% | +$150K |
|
2224
Liberty Energy
LBRT
$3.45B
| $802K | ﹤0.01% |
146,300
+35,900
| +33% | +$168K |
|
2225
Beam Therapeutics
BEAM
$2.74B
| $801K | ﹤0.01% |
+28,600
| New | +$616K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.